Drugmaker Bristol-Myers Squibb Inc. said Thursday that its fourth-quarter profit rose 8.6 percent, as reduced production and marketing costs and a big tax benefit offset a plunge in Plavix sales due to generic competition. Still, it beat Wall Street’s expectations.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.